A Phase II Clinical Study of SKB571 as Monotherapy in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer With MET Abnormalities
NCT ID: NCT07308106
Last Updated: 2025-12-29
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
NOT_YET_RECRUITING
PHASE2
60 participants
INTERVENTIONAL
2026-02-01
2029-03-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
SKB571 monotherapy
SKB571 for injection
SKB571 for injection is administered every 3 weeks(Q3W) .
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
SKB571 for injection
SKB571 for injection is administered every 3 weeks(Q3W) .
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Participants with histologically or cytologically confirmed NSCLC.
3. Locally advanced or metastatic NSCLC with MET Abnormalities that has progressed after standard therapy.
4. At least one measurable lesion as assessed by the investigator according to RECIST v1.1.
5. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 within 7 days before the first dose.
6. Life expectancy ≥ 3 months as assessed by the investigator.
7. Adequate organ and bone marrow function.
8. Male and female participants must agree to use highly effective methods of contraception during the study treatment period.
9. Participants must voluntarily join this study, sign the ICF, and be able to comply with the visits and related procedures specified in the protocol.
Exclusion Criteria
2. Participants with other malignant tumors within 3 years prior to the first dose.
3. Presence of any of the following cardiovascular and cerebrovascular diseases or cardiovascular and cerebrovascular risk factors.
4. Presence of severe and/or uncontrolled concomitant diseases.
5. Participants with a history of interstitial lung disease (ILD) or a history of non-infectious pneumonitis.
6. Clinically severe lung damage due to complications of lung disorder.
7. Risk of esophagotracheal fistula or esophagopleural fistula, or tumor invasion or compression of surrounding vital organs and blood vessels.
8. Toxicity from prior anti-tumor therapy has not recovered to ≤ Grade 1.
9. Known active pulmonary tuberculosis.
10. Known history of allogeneic organ transplant or allogeneic hematopoietic stem cell transplant.
11. Active hepatitis B and hepatitis C.
12. Positive test for human immunodeficiency virus (HIV) or a medical history of acquired immunodeficiency syndrome (AIDS); known active syphilis infection.
13. Known allergy or hypersensitivity to SKB571 or its excipients; or a history of severe allergy to other monoclonal antibodies.
14. Participants who have undergone major surgery within 4 weeks before the first dose or are expected to require major surgery during the study.
15. Serious infection within 4 weeks before the first dose.
16. Participants who have received systemic corticosteroid therapy with \> 10 mg/day of prednisone or other immunosuppressive drugs within 2 weeks before the first dose of study treatment.
17. Participants who have received a live vaccine within 30 days before the first dose, or plan to receive a live vaccine during the study.
18. Pregnant or breastfeeding women.
19. Have local or systemic diseases caused by non-malignant tumors, or diseases or symptoms secondary to tumors.
20. Any condition that, in the investigator's opinion, interferes with the evaluation of study treatment, participant safety, or interpretation of study results, or any other condition that the investigator deems unsuitable for participation in this study.
18 Years
75 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
SKB571-Ⅱ-03
Identifier Type: -
Identifier Source: org_study_id